NEW YORK (GenomeWeb) – Researchers have uncovered a common genetic variant that is associated with liver injury in multiple sclerosis patients who have been treated with interferon-β, suggesting a new way to pick out patients at risk of the adverse reaction.

IFN-βs are the most commonly used treatments for multiple sclerosis, but up to 60 percent of patients given the drug develop abnormal biochemical liver test results and 2 percent experience drug-induced liver injury.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.